Latest Conference Articles

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

Ankeet Bhatt, MD, MBA, discusses the effectiveness of text, email, and secure portal message reminders for encouraging patients to keep up with their treatment.

Leon Kircik, MD, on why an FDA-approved, at-home molluscum option changes practice, and what is exciting for him in dermatology.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Sharmila Dorbala, MD, MPH, discusses how this treatment and imaging strategy may lead to a diagnostic overhaul for patients with amyloidosis.

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.

Rahul Aggarwal, MD, MBA, shares the results of his retrospective cohort study investigating the residual risk of heart failure after patients with prior MI.

Olivier Sitbon, MD, PhD, reviews PDGF-targeted therapy in PAH, from imatinib's IMPRES trial to new prodrug and antibody approaches.

Pooled data from 3 trials show H-ISDN cuts all-cause and cardiovascular death in HFrEF, though heterogeneity limits clinical impact.

Dell discusses an analysis of VOYAGE showing dupilumab more than doubled the odds of favorable asthma outcomes in children, regardless of baseline ICS dose.

Castro, of University of Kansas discusses interim phase 1b data showing rapid, durable suppression in patients with mild to moderate asthma.

At ERS 2026, John Oppenheimer, MD, discusses how PERFORM supports earlier escalation in patients with uncontrolled, infrequently exacerbating asthma.

ADVANCE Outcomes at ERS 2026 demonstrated improved odds of improvement and reduced odds of worsening.

Charalambos Antoniades, MD, PhD, discusses the recent trial investigating an AI-powered stroke and atrial fibrillation predictor.

The oral RARβ/γ agonist improved FVC and reduced fibrotic biomarkers over 12 weeks in a phase 2a trial presented at the ERS Congress 2026.

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

Deepak Bhatt, MD, MPH, MBA, discusses the next steps for pacibekitug in cardiovascular disease following its success in the phase 2 trial.

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Ross Levy, MD, explains why the LEADderm Skin Angels panel matters and what dermatology innovation looks like in daily practice.

A post hoc ALPACA analysis presented at ESC Congress 2026 shows lepodisiran cut Lp(a)-bound oxidized phospholipids by up to 94% at the 400-mg dose.

Deepak Bhatt, MD, MPH, MBA, discusses the efficacy of this investigational IL-6 antibody among patients at high inflammatory risk.

Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, break down CARDIO-TTRansform and the new 2026 ESC heart failure guidelines.

The ASPIRED trial found immediate ECG monitoring in the ED did not reduce recurrent syncope but doubled arrhythmia detection and cut mortality.

The HCPLive editorial team previews late-breaking abstracts across COPD, asthma, IPF, PAH, and AATD ahead of ERS Congress 2026 in Barcelona.